CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial

CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial
An interim analysis from the Phase 2/3 clinical trial assessing Mateon Therapeutics' CA4P suggests the drug therapy is safe and effective in platinum-resistant ovarian cancer patients, when used in combination with physician's choice chemotherapy and Avastin (bevacizumab). "I am encouraged that the safety data is better than we expected and that the efficacy data is in line with our expectations," William D. Schwieterman, MD, Mateon's president and CEO, said in a press release. "After executing on the strategy we developed in late 2015, it is gratifying to be able to report new data for CA4P supporting its use in combination with bevacizumab and chemotherapy as a new treatment for platinum-resistant ovarian cancer. I am eager to see results from the additional interim analyses planned for later this year," he said. Mateon's CA4P (Combretastatin A4 phosphate) is a novel vascular disrupting agent that induces acute reductions in tumor blood flow. Used alone, CA4P has been shown to induce extensive cell death in a variety of cancer mouse models, and decrease blood flow in patient tumors. But pre-clinical and clinical data suggest that CA4P may be more effective when combined with radiotherapy or chemotherapy and with anti-angiogenic therapies, like Avastin, which prevent the formation of new blood vessels. The FOCUS Phase 2/3 trial (NCT02641639) is a randomized, double-blind, two-arm, para
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *